Literature DB >> 12473214

Immune therapy for EBV infections after hemopoietic stem-cell transplant.

H E Heslop1, C M Bollard, S Gottschalk, I Kuehnle, M H Huls, A P Gee, M K Brenner, C M Rooney.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2002        PMID： 12473214     DOI： 10.1080/146532402320776071

Source DB:  PubMed          Journal:  Cytotherapy        ISSN： 1465-3249            Impact factor:   5.414


× No keyword cloud information.
  4 in total

Review 1.  Strategies to prevent EBV reactivation and posttransplant lymphoproliferative disorders (PTLD) after allogeneic stem cell transplantation in high-risk patients.

Authors:  Nishitha Reddy; Katayoun Rezvani; A John Barrett; Bipin N Savani
Journal:  Biol Blood Marrow Transplant       Date:  2010-08-21       Impact factor: 5.742

2.  Preservation of Antigen-Specific Functions of αβ T Cells and B Cells Removed from Hematopoietic Stem Cell Transplants Suggests Their Use As an Alternative Cell Source for Advanced Manipulation and Adoptive Immunotherapy.

Authors:  Giuseppina Li Pira; Stefano Di Cecca; Simone Biagini; Elia Girolami; Elisabetta Cicchetti; Valentina Bertaina; Concetta Quintarelli; Ignazio Caruana; Barbarella Lucarelli; Pietro Merli; Daria Pagliara; Letizia Pomponia Brescia; Alice Bertaina; Mauro Montanari; Franco Locatelli
Journal:  Front Immunol       Date:  2017-03-23       Impact factor: 7.561

Review 3.  Genetic, cellular and immune approaches to disease therapy: past and future.

Authors:  Gary J Nabel
Journal:  Nat Med       Date:  2004-02       Impact factor: 53.440

4.  Clinical-grade generation of peptide-stimulated CMV/EBV-specific T cells from G-CSF mobilized stem cell grafts.

Authors:  Regina Gary; Michael Aigner; Stephanie Moi; Stefanie Schaffer; Anja Gottmann; Stefanie Maas; Robert Zimmermann; Jürgen Zingsem; Julian Strobel; Andreas Mackensen; Josef Mautner; Andreas Moosmann; Armin Gerbitz
Journal:  J Transl Med       Date:  2018-05-09       Impact factor: 5.531
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.